ConductScience.org, home

Paper26536626

Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China.

Toy M and 2 others. PLoS One, 2015. Cited by 19 papers, by iCite.

Cite this record

ConductScience Library. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. Papers, record 26536626. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26536626

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China.
PubMed
Journal
PLoS One
PubMed
Year
2015
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
19
iCite
Relative citation ratio, by iCite
0.76
iCite
Revised in PubMed
2022-04-08
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Toy MMehlika
2Hutton DWDavid W
3So SKSamuel K

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cost-Benefit AnalysisMajor topic
Hepatitis B, ChronicMajor topic
National Health ProgramsMajor topic
Antiviral Agents
China
Drugs, Generic
Guanine
Hepatitis B e Antigens
Humans
Markov Chains
Quality-Adjusted Life Years
Tenofovir

Source PubMed

Download CSV of topics

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116729316Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.Hepatology2006https://conductscience.org/library/papers/16729316PubMed
221036792Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.Gut2011https://conductscience.org/library/papers/21036792PubMed
318179664The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons.Value Health2008https://conductscience.org/library/papers/18179664PubMed
417133475Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.Hepatology2006https://conductscience.org/library/papers/17133475PubMed
519303414Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.Gastroenterology2009https://conductscience.org/library/papers/19303414PubMed
619918971Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B.Hepatology2010https://conductscience.org/library/papers/19918971PubMed
719669285Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.Hepatol Int2008https://conductscience.org/library/papers/19669285PubMed
819729084Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination.Vaccine2009https://conductscience.org/library/papers/19729084PubMed
919054588EASL Clinical Practice Guidelines: management of chronic hepatitis B.J Hepatol2009https://conductscience.org/library/papers/19054588PubMed
1024615378Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.Gut2014https://conductscience.org/library/papers/24615378PubMed
1119669245HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B.Hepatol Int2009https://conductscience.org/library/papers/19669245PubMed
1215602167Cost of chronic hepatitis B infection in China.J Clin Gastroenterol2004https://conductscience.org/library/papers/15602167PubMed
1319455130Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus.Am J Gastroenterol2009https://conductscience.org/library/papers/19455130PubMed
1420483498Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.J Hepatol2010https://conductscience.org/library/papers/20483498PubMed
1517192114Rates and probabilities in economic modelling: transformation, translation and appropriate application.Pharmacoeconomics2007https://conductscience.org/library/papers/17192114PubMed
1617310821Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.Antivir Ther2006https://conductscience.org/library/papers/17310821PubMed
1723364953Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.Hepatology2013https://conductscience.org/library/papers/23364953PubMed
1812823597Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.J Viral Hepat2003https://conductscience.org/library/papers/12823597PubMed
1917499584Hepatitis B in China.Lancet2007https://conductscience.org/library/papers/17499584PubMed
2016461777Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil.Gut2006https://conductscience.org/library/papers/16461777PubMed

See all 49 referencesDownload CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.

PMIDTitleJournalYearIn PapersSource
35801242Cost-Benefit Analysis of Vaccination Strategies to Prevent Mother-to-Child Transmission of the Hepatitis B Virus Using a Markov Model Decision Tree.Front Public Health2022https://conductscience.org/library/papers/35801242PubMed
35796158Costs and health impact of delayed implementation of a national hepatitis B treatment program in China.J Glob Health2022https://conductscience.org/library/papers/35796158PubMed
34427860APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy.Hepatol Int2021https://conductscience.org/library/papers/34427860PubMed
33248510Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.Value Health2020https://conductscience.org/library/papers/33248510PubMed
33197397Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2021https://conductscience.org/library/papers/33197397PubMed
32854458Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop.Clin Mol Hepatol2020https://conductscience.org/library/papers/32854458PubMed
31574103Development and application of a framework to estimate health care costs in China: The cervical cancer example.PLoS One2019https://conductscience.org/library/papers/31574103PubMed
31428938Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review.Pharmacoecon Open2020https://conductscience.org/library/papers/31428938PubMed
30931346Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States.Open Forum Infect Dis2019https://conductscience.org/library/papers/30931346PubMed
29633520How far are we from viral hepatitis elimination service coverage targets?J Int AIDS Soc2018https://conductscience.org/library/papers/29633520PubMed
29447614Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B.Glob Health Action2018https://conductscience.org/library/papers/29447614PubMed
28963103The role of routine screening in blood-borne pathogens in Chinese patients undergoing joint arthroplasty.Bone Joint Res2017https://conductscience.org/library/papers/28963103PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26536626

GET https://conductscience.org/api/papers/v1/26536626/references?page=2